Omeros (OMER) Times Interest Earned (2010 - 2026)
Omeros recorded quarterly Times Interest Earned of -$2.96 in Q1 2026, up 11.31% quarter-over-quarter from -$3.33 in Q4 2025, and up 69.11% year-over-year from -$1.75 in Q1 2025.
Omeros' Times Interest Earned history runs 17 years deep, the most recent figure standing at -$2.96 for Q1 2026.
- In Q1 2026, Times Interest Earned rose 69.11% year-over-year to -$2.96; the TTM figure through Mar 2026 stood at -$82.22 (down 914.54% YoY), while the FY2025 annual figure was $127.91, up 138.31% from the prior year.
- Times Interest Earned came in at -$2.96 for Q1 2026 at Omeros, up from -$3.33 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $1.98 in Q3 2025 to a low of -$2156.9 in Q2 2025.
- A 5-year average of -$132.51 and a median of -$6.08 in 2023 frame the typical range for Times Interest Earned.
- On a YoY basis, Times Interest Earned climbed as much as 122.62% in 2025 and fell as far as 33498.97% in 2025.
- Omeros' Times Interest Earned stood at -$5.08 in 2022, then dropped by 10.85% to -$5.63 in 2023, then tumbled by 86.48% to -$10.5 in 2024, then surged by 68.26% to -$3.33 in 2025, then gained by 11.31% to -$2.96 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$2.96, -$3.33, and $1.98 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn | -2.96 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.96 |
| Dec 31, 2025 | -3.33 |
| Sep 30, 2025 | 1.98 |
| Jun 30, 2025 | -2,156.93 |
| Mar 31, 2025 | -9.57 |
| Dec 31, 2024 | -10.50 |
| Sep 30, 2024 | -8.74 |
| Jun 30, 2024 | -6.42 |
| Mar 31, 2024 | -4.74 |
| Dec 31, 2023 | -5.63 |
| Sep 30, 2023 | -6.08 |
| Jun 30, 2023 | -5.16 |
| Mar 31, 2023 | -4.50 |
| Dec 31, 2022 | -5.08 |
| Sep 30, 2022 | -10.29 |
| Jun 30, 2022 | -7.60 |
| Mar 31, 2022 | -7.09 |
| Dec 31, 2021 | -8.66 |
| Sep 30, 2021 | -8.11 |
| Jun 30, 2021 | -9.29 |
| Mar 31, 2021 | -9.25 |
| Dec 31, 2020 | -4.23 |
| Sep 30, 2020 | -3.69 |
| Jun 30, 2020 | -4.63 |
| Mar 31, 2020 | -4.01 |
| Dec 31, 2019 | -4.08 |
| Sep 30, 2019 | -1.94 |
| Jun 30, 2019 | -1.69 |
| Mar 31, 2019 | -3.44 |
| Dec 31, 2018 | -3.59 |
| Sep 30, 2018 | -7.70 |
| Jun 30, 2018 | -8.33 |
| Mar 31, 2018 | -9.80 |
| Dec 31, 2017 | -4.93 |
| Sep 30, 2017 | -1.84 |
| Jun 30, 2017 | -4.38 |
| Mar 31, 2017 | -4.78 |
| Dec 31, 2016 | -4.84 |
| Sep 30, 2016 | -5.64 |
| Jun 30, 2016 | -5.89 |
| Mar 31, 2016 | -14.15 |
| Dec 31, 2015 | -22.33 |
| Sep 30, 2015 | -22.16 |
| Jun 30, 2015 | -17.04 |
| Mar 31, 2015 | -18.74 |
| Dec 31, 2014 | -21.83 |
| Sep 30, 2014 | -18.15 |
| Jun 30, 2014 | -18.34 |
| Mar 31, 2014 | -23.34 |
| Dec 31, 2013 | -23.25 |
| Sep 30, 2013 | -22.69 |
| Jun 30, 2013 | -22.34 |
| Mar 31, 2013 | -17.07 |
| Dec 31, 2012 | -20.41 |
| Sep 30, 2012 | -31.56 |
| Jun 30, 2012 | -18.20 |
| Mar 31, 2012 | -16.34 |
| Dec 31, 2011 | -18.37 |
| Sep 30, 2011 | -11.67 |
| Jun 30, 2011 | -9.39 |
| Mar 31, 2011 | -22.01 |
| Dec 31, 2010 | -27.43 |
| Sep 30, 2010 | -20.69 |
| Jun 30, 2010 | -18.67 |